<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Article Antiviral Effect of Epigallocatechin Gallate via Impairing Porcine Circovirus" exact="Type 2" post="Attachment to Host Cell Receptor LiJiarong1SongDongfeng1WangShengnan12DaiYadong23ZhouJiyong23GuJinyan1*[1], 2015207025@njau.edu.cn2017107087@njau.edu.cnwangshengnanwsnj@163.com[2], 11817028@zju.edu.cnjyzhou@zju.edu.cn[3], *Correspondence:"/>
 <result pre="we demonstrated the antiviral effect of EGCG on porcine circovirus" exact="type 2" post="(PCV2). EGCG targets PCV2 virions directly and blocks the"/>
 <result pre="the development and synthesis of structure-based anti-circovirus drugs. Porcine circovirus" exact="type 2" post="epigallocatechin gallate heparan sulfate antiviral effect virus attachment 1."/>
 <result pre="from plants to animals with different pathogenicities [2]. Porcine circovirus" exact="type 2" post="(PCV2) is a prototype circovirus that causes significant morbidity"/>
 <result pre="associated with different syndromes, such as the post-weaning multisystemic wasting" exact="syndrome" post="[6,7] and reproductive disorder [8]. The genome of PCV2"/>
 <result pre="(ORFs). ORF1 encodes the replicase protein (Rep) involved in rolling-circle" exact="viral" post="DNA replication, while ORF2 encodes the unique viral structural"/>
 <result pre="in rolling-circle viral DNA replication, while ORF2 encodes the unique" exact="viral" post="structural protein capsid [9], which is involved in diverse"/>
 <result pre="which is involved in diverse and essential biological events during" exact="virus infection," post="such as virion attachment [10]. The primary attachment of"/>
 <result pre="events during virus infection, such as virion attachment [10]. The" exact="primary" post="attachment of the non-enveloped virus on the host cells"/>
 <result pre="the host cells is based on a low-affinity interaction between" exact="viral" post="structural protein and cell surface glycosaminoglycans (GAGs) receptors [11,12]."/>
 <result pre="by viruses for attachment to cell surfaces, such as the" exact="hepatitis" post="C virus [14], herpes simplex virus 1 [15], human"/>
 <result pre="to cell surfaces, such as the hepatitis C virus [14]," exact="herpes" post="simplex virus 1 [15], human enterovirus 71 [16] and"/>
 <result pre="herpes simplex virus 1 [15], human enterovirus 71 [16] and" exact="rabies" post="virus [17]. PCV2 has also been verified to use"/>
 <result pre="activities [19]. However, there are very few reports of PCV2" exact="infection" post="inhibition available for pertaining to such natural small molecule"/>
 <result pre="major component of GTCs accounting for approximately 59% of the" exact="total" post="polyphenols, and it is also the most complicated and"/>
 <result pre="the most complicated and principal constituent, possessing the activity against" exact="infection" post="of several viruses, such as human immunodeficiency virus (HIV)"/>
 <result pre="the activity against infection of several viruses, such as human" exact="immunodeficiency" post="virus (HIV) [26], influenza A virus [27], Zika virus"/>
 <result pre="virus (HIV) [26], influenza A virus [27], Zika virus [28]," exact="herpes" post="simplex viruses 1 [29], and hepatitis C virus [30]."/>
 <result pre="[27], Zika virus [28], herpes simplex viruses 1 [29], and" exact="hepatitis" post="C virus [30]. The mechanisms of EGCG antiviral activity"/>
 <result pre="antiviral activity are complicated and diverse, depending on the specific" exact="virus infection" post="process or host cell response, one of which is"/>
 <result pre="activity are complicated and diverse, depending on the specific virus" exact="infection" post="process or host cell response, one of which is"/>
 <result pre="cell response, one of which is that EGCG interacts with" exact="viral" post="structural proteins, consequently blocking the latter from recognizing or"/>
 <result pre="[31]. Regarding the GAGs receptors, EGCG could bind to the" exact="herpes" post="simplex virus-1 glycoprotein gB and gD, which should interact"/>
 <result pre="2. Materials and Methods 2.1. Cells and Virus PCV-free Porcine" exact="Kidney" post="15 (PK15) (BH0370, ATCC, Manassas, VA, USA) cells were"/>
 <result pre="conjugated goat anti-mouse IgG (074-1802, KPL, Milford, MA, USA) and" exact="Mouse" post="IgG1 Isotype Control (564416, BD Horizon™, San Jose, CA,"/>
 <result pre="capsid and FITC-conjugated goat anti-mouse IgG. The 50% tissue culture" exact="infective" post="dose (TCID50) was calculated according to the Reed-Muench method."/>
 <result pre="was calculated according to the Reed-Muench method. The multiplicity of" exact="infection" post="(MOI) was defined as the number of plaques forming"/>
 <result pre="antibody and HRP- goat anti-mouse IgG; copy numbers of the" exact="viral" post="genome were determined with quantitative real-time PCR (qRT-PCR) with"/>
 <result pre="(Version 10.0.7, FlowJo, San Jose, CA, USA ). 2.9. Recombinant" exact="Protein" post="Expression and Purification The engineered dcapsid (capsid with N-terminal"/>
 <result pre="2.1, NanoTemper Technologies, Munich, Bavaria, Germany). 2.12. Construction of PCV2" exact="Infectious" post="Clone and Virus Rescue The whole genome of PCV2"/>
 <result pre="concentration of 200 μM could produce cytotoxicity to cells, which" exact="limited" post="the maximum concentration of EGCG at 100 μM (Figure"/>
 <result pre="inhibited at the 100 μM EGCG treatment during the whole" exact="infective" post="process, the virus titer of PCV2 infected cells with"/>
 <result pre="of PCV2 infectivity was also manifested by reduced level of" exact="viral" post="capsid protein expression measured by immunoblotting (Figure 1d), and"/>
 <result pre="expression measured by immunoblotting (Figure 1d), and the reduction of" exact="viral" post="genome copy number detected by qPCR (Figure 1e) at"/>
 <result pre="the 100 μM EGCG treatment. The inhibitory effect of PCV2" exact="infection" post="was still detectable for the 10 μM EGCG treatment"/>
 <result pre="infected cells with the 100 μM EGCG treatment was obviously" exact="lower" post="than that without EGCG treatment (Figure 1f). The original"/>
 <result pre="by targeting PCV2 virions, such as the effect on certain" exact="viral" post="nucleic acids and proteins, or targeting host cells [23]."/>
 <result pre="cells group (Figure 2a), which was consistent with results of" exact="viral" post="nucleic acid and titer determination (Figure 2b,c). Meanwhile, the"/>
 <result pre="cells, ensuring the cells were treated with compound at 10-fold" exact="lower" post="concentrations (10 μM) than the viral particles; in such"/>
 <result pre="with compound at 10-fold lower concentrations (10 μM) than the" exact="viral" post="particles; in such a way, the inhibitory phenomenon would"/>
 <result pre="the EGCG antiviral effect could be active during the PCV2" exact="infective" post="process, EGCG was added post-infection and incubated for various"/>
 <result pre="indicating that EGCG might work at the early stage of" exact="infection" post="course. Thereby, the binding assay was performed, the virions"/>
 <result pre="PCV2 virions attached to host cells via direct interaction between" exact="viral" post="capsid protein and cell surface heparan sulfate [10]. Therefore,"/>
 <result pre="PCV2 infection, could also bind to capsid with a 10-fold" exact="lower" post="affinity than EGCG (Kd = 951.33 ± 6.81 μM)"/>
 <result pre="could elute 89.33 ± 4.16% and 90.00 ± 5.29% of" exact="total" post="protein, respectively (Figure 4e), and the difference between then"/>
 <result pre="1061.33 ± 8.08 μM, respectively (Figure 6c,f), almost 10 times" exact="lower" post="than the Kd of WT to EGCG (Kd ="/>
 <result pre="surface, which eventually lead to the inability of virions to" exact="complete" post="the infection process [18]. We next performed the infectivity"/>
 <result pre="eventually lead to the inability of virions to complete the" exact="infection" post="process [18]. We next performed the infectivity assay of"/>
 <result pre="mutant viruses with 100 μM EGCG treatment during the whole" exact="infective" post="process. The titers of mutant viruses were detected at"/>
 <result pre="antiviral effect of EGCG could not be detected during the" exact="infection" post="of PCV2 (D70A) and PCV2 (D78A) (Figure 7g,i), These"/>
 <result pre="showed that EGCG exhibited an inhibitory effect on the PCV2" exact="infection" post="at the concentration of 100 μM, without causing significant"/>
 <result pre="residue and the other is an anionic acid. HS chains" exact="acquired" post="negative charge though epimerization and terminal sulfation processes, thereby"/>
 <result pre="signaling pathway proteins, growth factors, plasma proteins, immune modulators and" exact="viral" post="structural proteins [39]. In general, these protein ligands possessed"/>
 <result pre="showed similar antiviral activity against various viruses, EGCG inhibited the" exact="infection" post="of PRRSV with an EC50 of 48.2–63.09 μM in"/>
 <result pre="clinical virus infections, the identification of key amino acids of" exact="viral" post="proteins that bind EGCG is valuable for the development"/>
 <result pre="is decreased to 5.86–12.69 μM, which is nearly 5 times" exact="lower" post="than for the original EGCG [45]. On the other"/>
 <result pre="circoviruses—Small but powerfulVirus Res.200914317718310.1016/j.virusres.2009.02.00919647885 4.OuyangT.ZhangX.LiuX.RenL.Co-Infection of Swine with Porcine Circovirus" exact="Type 2" post="and Other Swine VirusesViruses20191118510.3390/v1102018530795620 5.AfolabiK.O.IwerieborB.C.OkohA.I.ObiL.C.Global Status of Porcine circovirus"/>
 <result pre="2 and Other Swine VirusesViruses20191118510.3390/v1102018530795620 5.AfolabiK.O.IwerieborB.C.OkohA.I.ObiL.C.Global Status of Porcine circovirus" exact="Type 2" post="and Its Associated Diseases in Sub-Saharan AfricaAdv. Virol.20172017680796410.1155/2017/680796428386278 6.HamelA.L.LinL.L.NayarG.P.Nucleotide"/>
 <result pre="5.AfolabiK.O.IwerieborB.C.OkohA.I.ObiL.C.Global Status of Porcine circovirus Type 2 and Its Associated" exact="Diseases" post="in Sub-Saharan AfricaAdv. Virol.20172017680796410.1155/2017/680796428386278 6.HamelA.L.LinL.L.NayarG.P.Nucleotide sequence of porcine circovirus"/>
 <result pre="6.HamelA.L.LinL.L.NayarG.P.Nucleotide sequence of porcine circovirus associated with postweaning multisystemic wasting" exact="syndrome" post="in pigsJ. Virol.1998725262526710.1128/JVI.72.6.5262-5267.19989573301 7.AllanG.M.KennedyS.McNeillyF.FosterJ.C.EllisJ.A.KrakowkaS.J.MeehanB.M.AdairB.M.Experimental reproduction of severe wasting disease"/>
 <result pre="wasting syndrome in pigsJ. Virol.1998725262526710.1128/JVI.72.6.5262-5267.19989573301 7.AllanG.M.KennedyS.McNeillyF.FosterJ.C.EllisJ.A.KrakowkaS.J.MeehanB.M.AdairB.M.Experimental reproduction of severe wasting" exact="disease" post="by co-infection of pigs with porcine circovirus and porcine"/>
 <result pre="porcine circovirus and porcine parvovirusJ. Comp. Pathol.199912111110.1053/jcpa.1998.029510373289 8.SanchezR.E.Jr.NauwynckH.J.McNeillyF.AllanG.M.PensaertM.B.Porcine circovirus 2" exact="infection" post="in swine foetuses inoculated at different stages of gestationVet."/>
 <result pre="of gestationVet. Microbiol.20018316917610.1016/S0378-1135(01)00425-411557157 9.NawagitgulP.MorozovI.BolinS.R.HarmsP.A.SordenS.D.PaulP.S.Open reading frame 2 of porcine circovirus" exact="type 2" post="encodes a major capsid proteinJ. Gen. Virol.2000812281228710.1099/0022-1317-81-9-228110950986 10.MisinzoG.DelputteP.L.MeertsP.LefebvreD.J.NauwynckH.J.Porcine circovirus"/>
 <result pre="to and invasion through proteoglycansInfect. Immun.1997651810.1128/IAI.65.1.1-8.19978975885 12.CagnoV.TseligkaE.D.JonesS.T.TapparelC.Heparan Sulfate Proteoglycans and" exact="Viral" post="Attachment: True Receptors or Adaptation Bias?Viruses20191159610.3390/v1107059631266258 13.PrydzK.DalenK.T.Synthesis and sorting"/>
 <result pre="Bias?Viruses20191159610.3390/v1107059631266258 13.PrydzK.DalenK.T.Synthesis and sorting of proteoglycansJ. Cell Sci.200011319320510633071 14.XuY.MartinezP.SeronK.LuoG.AllainF.DubuissonJ.BelouzardS.Characterization of" exact="hepatitis" post="C virus interaction with heparan sulfate proteoglycansJ. Virol.2015893846385810.1128/JVI.03647-1425609801 15.ShiehM.T.WuDunnD.MontgomeryR.I.EskoJ.D.SpearP.G.Cell"/>
 <result pre="interaction with heparan sulfate proteoglycansJ. Virol.2015893846385810.1128/JVI.03647-1425609801 15.ShiehM.T.WuDunnD.MontgomeryR.I.EskoJ.D.SpearP.G.Cell surface receptors for" exact="herpes" post="simplex virus are heparan sulfate proteoglycansJ. Cell Biol.19921161273128110.1083/jcb.116.5.12731310996 16.TanC.W.PohC.L.SamI.C.ChanY.F.Enterovirus"/>
 <result pre="effects of (-)-epigallocatechin gallate on the life cycle of human" exact="immunodeficiency" post="virus type 1 (HIV-1)Antivir. Res.200253193410.1016/S0166-3542(01)00189-911684313 27.NakayamaM.SuzukiK.TodaM.OkuboS.HaraY.ShimamuraT.Inhibition of the infectivity"/>
 <result pre="(-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus" exact="type 1" post="(HIV-1)Antivir. Res.200253193410.1016/S0166-3542(01)00189-911684313 27.NakayamaM.SuzukiK.TodaM.OkuboS.HaraY.ShimamuraT.Inhibition of the infectivity of influenza virus"/>
 <result pre="Zika virus entryVirology201649621521810.1016/j.virol.2016.06.01227344138 29.IsaacsC.E.WenG.Y.XuW.JiaJ.H.RohanL.CorboC.Di MaggioV.JenkinsE.C.Jr.HillierS.Epigallocatechin gallate inactivates clinical isolates of" exact="herpes" post="simplex virusAntimicrob. Agents Chemother.20085296297010.1128/AAC.00825-0718195068 30.CiesekS.von HahnT.ColpittsC.C.SchangL.M.FrieslandM.SteinmannJ.MannsM.P.OttM.WedemeyerH.MeulemanP.et al.The green tea"/>
 <result pre="Agents Chemother.20085296297010.1128/AAC.00825-0718195068 30.CiesekS.von HahnT.ColpittsC.C.SchangL.M.FrieslandM.SteinmannJ.MannsM.P.OttM.WedemeyerH.MeulemanP.et al.The green tea polyphenol, epigallocatechin-3-gallate, inhibits" exact="hepatitis" post="C virus entryHepatology2011541947195510.1002/hep.2461021837753 31.KawaiK.TsunoN.H.KitayamaJ.OkajiY.YazawaK.AsakageM.HoriN.WatanabeT.TakahashiK.NagawaH.Epigallocatechin gallate, the main component of"/>
 <result pre="Immunol.200311295195710.1016/S0091-6749(03)02007-414610487 32.O’DonnellC.D.KovacsM.AkhtarJ.Valyi-NagyT.ShuklaD.Expanding the role of 3-O sulfated heparan sulfate in" exact="herpes" post="simplex virus type-1 entryVirology201039738939810.1016/j.virol.2009.11.01120004926 33.ZhouJ.Y.ChenQ.X.YeJ.X.ShenH.G.ChenT.F.ShangS.B.Serological investigation and genomic characterization"/>
 <result pre="monoclonal antibody and bioactivity for capsid protein of porcine circovirus" exact="type II" post="without nuclear localization signalJ. Biotechnol.200511820121110.1016/j.jbiotec.2005.02.01715964652 35.HjulsagerC.K.Grau-RomaL.SibilaM.EnoeC.LarsenL.SegalesJ.Inter-laboratory and inter-assay comparison"/>
 <result pre="43.GeM.XiaoY.ChenH.LuoF.DuG.ZengF.Multiple antiviral approaches of (-)-epigallocatechin-3-gallate (EGCG) against porcine reproductive and" exact="respiratory" post="syndrome virus infection in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the"/>
 <result pre="antiviral approaches of (-)-epigallocatechin-3-gallate (EGCG) against porcine reproductive and respiratory" exact="syndrome" post="virus infection in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the early"/>
 <result pre="approaches of (-)-epigallocatechin-3-gallate (EGCG) against porcine reproductive and respiratory syndrome" exact="virus infection" post="in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the early stages of"/>
 <result pre="of (-)-epigallocatechin-3-gallate (EGCG) against porcine reproductive and respiratory syndrome virus" exact="infection" post="in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the early stages of"/>
 <result pre="infection in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the early stages of" exact="Japanese encephalitis" post="virus infectionVirus Res.201825314014610.1016/j.virusres.2018.06.00929958923 45.ZhaoC.LiuS.LiC.YangL.ZuY.In vitro evaluation of the antiviral"/>
 <result pre="in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the early stages of Japanese" exact="encephalitis" post="virus infectionVirus Res.201825314014610.1016/j.virusres.2018.06.00929958923 45.ZhaoC.LiuS.LiC.YangL.ZuY.In vitro evaluation of the antiviral"/>
 <result pre="epigallocatechin gallate analog-epigallocatechin gallate (EGCG) palmitate against porcine reproductive and" exact="respiratory" post="syndrome virusViruses2014693895010.3390/v602093824566281 Figure 1 EGCG exhibits an anti-viral effect"/>
 <result pre="gallate analog-epigallocatechin gallate (EGCG) palmitate against porcine reproductive and respiratory" exact="syndrome" post="virusViruses2014693895010.3390/v602093824566281 Figure 1 EGCG exhibits an anti-viral effect on"/>
 <result pre="without EGCG. At 72 hpi PCV2 infectivity was assessed by" exact="viral" post="protein expression (a), viral genome copies (b), and virus"/>
 <result pre="hpi PCV2 infectivity was assessed by viral protein expression (a)," exact="viral" post="genome copies (b), and virus titers (c). (d–f) Virions"/>
 <result pre="= 1.0 with 100 μM EGCG treatment during the whole" exact="infective" post="process and the titers were detected by IFA at"/>
</results>
